Balyasny Asset Management
FLXN

Balyasny Asset Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Balyasny Asset Management’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-475,000
Closed -$9.83M – 1639
2019
Q4 		$9.83M Buy
475,000
+275,000
+138% +$4.64M 0.06% 436
2019
Q3 		$2.74M Buy
+200,000
New +$2.37M 0.02% 663

Other funds holding FLXN

MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Balyasny Asset Management's FLXN Position: Q3 2020 in Review

Balyasny Asset Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q3 2020, closing a stake of 474,518 shares — an estimated $6.24M sold.

Balyasny Asset Management first reported a position in FLXN in Q4 2017 and held it in 7 quarters. The position peaked at $8.22M in Q4 2019. 135 funds tracked by Wall St. Rank hold FLXN as of Q3 2020.

  • Balyasny Asset Management reported no remaining Flexion Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Balyasny Asset Management sold 474,518 Flexion Therapeutics, Inc. shares in Q3 2020, an estimated $6.24M.
  • Balyasny Asset Management first reported a position in Flexion Therapeutics, Inc. in Q4 2017 and held it in 7 quarters.
  • Balyasny Asset Management's Flexion Therapeutics, Inc. position peaked at $8.22M in Q4 2019.
  • 135 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2020.

Based on Balyasny Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.